Fluorescent ligands of the bradykinin B receptors: Pharmacologic characterization and application to the study of agonist-induced receptor translocation and cell surface receptor expression

Journal of Pharmacology and Experimental Therapeutics

Volumn 329, Issue 1, 2009, Pages 159-168

  Bawolak, Marie Thérèse ^a   Gera, Lajos ^b   Morissette, Guillaume ^a   Bouthillier, Johanne ^a   Stewart, John M ^b   Gobeil, Lise Andree ^a   Lodge, Robert ^a   Adam, Albert ^c   Marceau, François ^a  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

6 CARBOXYFLUORESCEIN; AMASTATIN; B 10372; B 10376; B 10378; B 9958; BRADYKININ B1 RECEPTOR; BRADYKININ B1 RECEPTOR AGONIST; BRADYKININ B1 RECEPTOR ANTAGONIST; CAVEOLIN 1; CELL SURFACE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA CONSTRICTION; ARTICLE; BINDING AFFINITY; CALCIUM MOBILIZATION; CELL STRAIN HEK293; CONTROLLED STUDY; CYTOFLUOROMETRY; DRUG BINDING; DRUG SYNTHESIS; GENE TRANSLOCATION; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABBIT; SMOOTH MUSCLE FIBER;

ANIMALS; AORTA, THORACIC; BINDING, COMPETITIVE; BRADYKININ; CALCIUM SIGNALING; CELL LINE; CELL MEMBRANE; FLUORESCENT DYES; HUMANS; INDICATORS AND REAGENTS; LIGANDS; MICROSCOPY, FLUORESCENCE; MUSCLE CONTRACTION; PROTEIN TRANSPORT; RABBITS; RECEPTOR, BRADYKININ B1; RECEPTORS, CELL SURFACE;

EID: 63849308514     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.108.149724     Document Type: Article

References (25)

1. 1 receptor mediates inhibition of neointima formation in rat artery after balloon angioplasty. Hypertension 36:364-370.
2. 2 receptor antagonist B-9430: pharmacological characterization and use in live cell imaging. Peptides 29:1626-1630.
3. 1 receptor and COX2, in the rabbit: effect of LPS, anti-inflammatory and antihypertensive drugs. Regul Pept 146:157-168.
4. 2receptors and phosphatidylinositol 3-kinase γ Mol Pharmacol 66:293-301.
5. 50)of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
6. Duchardt F, Fotin-Mleczek M, Schwarz H, Fischer R, and Brock R (2007) Acompre - hensive model for the cellular uptake of cationic cell-penetrating peptides. Traffic 8:848-866.
7. Emanueli C, Bonaria Salis M, Stacca T, Pintus G, Kirchmair R, Isner JM, Pinna A, Gaspa L, Regoli D, Cayla C, et al. (2002) Targeting kinin B1 receptor for thera peutic neovascularization. Circulation 105:360-366.
8. Fortin JP, Bouthillier J, and Marceau F (2003) High agonist-independent clearance of rabbit kinin B1 receptors in cultured cells. Am J Physiol Heart Circ Physiol 284:H1647-H1654.
9. Fortin JP, Gera L, Bouthillier J, Stewart JM, Adam A, and Marceau F (2005a) Endogenous aminopeptidase N decreases the potency of peptide agonists and antagonists of the kinin B1 receptors in the rabbit aorta. J Pharmacol Exp Ther 314:1169-1176.
10. Fortin JP, Rivard GE, Adam A, and Marceau F (2005b) Studies on rabbit natural and recombinant tissue factors: intracellular retention and regulation of surface expression in cultured cells. Am J Physiol Heart Circ Physiol 288:H2192-H2202.
11. 1 receptor antagonism. J Pharmacol Exp Ther 317:300-308.
12. Gera L, Stewart JM, Fortin JP, Morissette G, and Marceau F (2008) Structural modification of the highly potent peptide bradykinin B1 receptor antagonist B9958. Int Immunopharmacol 8:289 - 292.
13. Gera L, Stewart JM, Whalley ET, Burkard M, and Zuzack JS (1996) New bradykinin antagonists having high potency at B1 receptors. Immunopharmacology 33:183-185.
14. 1 receptor. Br J Pharmacol 131:885-892.
15. Leeb-Lundberg LM, Marceau F, Muller-Esterl W, Pettibone DJ, and Zuraw BL (2005) International Union of Pharmacology: XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharm Rev 57:27-77.
16. Levesque L, Harvey N, Rioux F, Drapeau G, and Marceau F (1995) Development of a binding assay for the B1 receptors for kinins. Immunopharmacology 29:141-147.
17. 1 receptor in human vascular smooth muscle cells. Mol Pharmacol 71:949 - 956.
18. 1receptors. Peptides 29: 606-612.
19. Morissette G, Fortin JP, Otis S, Bouthillier J, and Marceau F (2004) A novel nonpeptide antagonist of the kinin B1 receptor: effects at the rabbit receptor. J Pharmacol Exp Ther 311:1121-1130.
20. Morissette G, Sabourin T, Adam A, and Marceau F (2006) Inhibition of human and rabbit arterial smooth muscle cell migration mediated by the kinin B1 receptor: role of receptor density and released mediators. Can J Physiol Pharmacol 84: 1107-1119.
21. Ostrom RS (2002) New determinants of receptor-effector coupling: trafficking and compartmentation in membrane microdomains. Mol Pharmacol 61:473-476.
22. Pelkmans L, Kartenbeck J, and Helenius A (2001) Caveolar endocytosis of simian virus 40 reveals a new two-step vesicular-transport pathway to the ER. Nat Cell Biol 3:473-483.
23. Prat A, Biernacki K, Saroli T, Orav JE, Guttmann CR, Weiner HL, Khoury SJ, and Antel JP (2005) Kinin B1 receptor expression on multiple sclerosis mononuclear cells: correlation with magnetic resonance imaging T2-weighted lesion volume and clinical disability. Arch Neurol 62:795-800.
24. Sabourin T, Bastien L, Bachvarov DR, and Marceau F (2002) Agonist-induced translocation of the kinin B1 receptor to caveolae-related rafts. Mol Pharmacol 61:546 - 553.
25. Tallarida RJ and Murray RB (1987) Manual ofPharmacologic Calculations with Computer Programs, Springer, New York.